Mitch Brown was preparing last August to launch a follow-up study to a 2021 paper on coalitions when he found something in his computer coding that sent his stomach to his shoes.
As Brown, an experimental psychologist at the University of Arkansas, recalled for us:
An ob-gyn journal has retracted a clinically influential 2016 paper on the use of steroids in women undergoing cesarean delivery, citing questions about the data.
The study purported to involve nearly 1,300 women – making it the largest analysis of women receiving steroids for the indication in the trial. But Ben Mol, an ob-gyn researcher and data sleuth at Monash Medical Centre in Australia, noted that the paper – which has been cited 32 times, per Clarivate Analytics’ Web of Science – was based on a thesis by the second author, M.M. Shafeek. Something in the two articles caught Mol’s eye, he told Retraction Watch:
A pharmacology researcher at the University of Pennsylvania is up to four retractions for problems with the data in his articles after a neurology journal pulled three papers late last month.
According to the Journal of Neurotrauma, a Mary Ann Liebert title, William Armstead – who holds a research professorship in Anesthesiology and Critical Care at Penn [please see an update on this post] – requested the retraction of three articles while informing that, in his words:
substantive questions have arisen regarding the findings, presentation and conclusions reported in the paper that could not be answered with available source data.
But beyond that, Armstead – who has not responded to a request for comment from Retraction Watch – left things a bit of a mystery.
A researcher who guest edited an issue has lost two papers after a journal’s publisher discovered that he had changed his name on the manuscripts following submission.
The journal Cureus has issued expressions of concern for a whopping 55 papers whose authorship has come into question.
The articles, including a couple like this one on COVID-19, were apparently submitted as part of an effort by Imam Abdulrahman Bin Faisal University, in Saudi Arabia, to pad the publishing resumes of its medical students – and perhaps the school’s own metrics – who targeted Cureus for reasons that aren’t now clear.
Here’s the notice for “Sylvian Fissure Lipoma: An Unusual Etiology of Seizures in Adults,” which the journal published in January 2022:
Funding for the study – which has been cited 57 times, according to Clarivate Analytics’ Web of Science – came from the Japanese government and the Uehara Memorial Foundation. Hokkaido is now investigating, Science said.
A group of nanotechnology researchers in Iran is up to nine retractions after losing four papers in a go for problematic figures.
The work was led by Abolfazl Akbarzadeh, a medicinal chemist at Tabriz University of Medical Sciences, who has spent time as a visiting professor at Boston University and UCLA. Commenters on PubPeer including Elisabeth Bik and “Hoya camphorifolia” have raised questions about the papers, with posts dating back to November 2020.
The latest retractions involve articles that appeared in Artificial Cells, Nanomedicine, and Biotechnology, a Taylor & Francis title. Evidently, the papers appear to have had…artificial data.
Two and a half years after critics raised concerns, a dermatology journal says it has called on two French institutions to launch an inquiry into a 2017 paper.
The Journal of Investigative Dermatology has issued an expression of concern for the article, “NADPH Oxidase-1 Plays a Key Role in Keratinocyte Responses to UV Radiation and UVB-Induced Skin Carcinogenesis,” which it published in June 2017.
The authors of the group were led by Hamid Reza Rezvani, the head of the dermatology team at Université de Bordeaux, and a research director with INSERM, France’s publicly funded science agency.